Stay updated with breaking news from Binding Affinity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The study findings showed that the rapid antigen tests with the DMS approach could accurately identify antibody escape mutations in the SARS-CoV-2 N protein.
In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).
A recent report published in the STAR Protocols journal depicted a protocol for an antibody-based proximity labeling to discover biotinylated interactors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
In a new study, researchers described their self-designed chimeric receptor-binding domain-dimer vaccine approach to adapt SARS-CoV-2 variants of concern and variants of interest.
The current study, escribes a new mAb LY-CoV1404 (bebtelovimab) from Eli Lilly, with high neutralization potency with a broad spectrum of activity across all current variants.